The Study
Immunotherapy-related cognitive impairment after CAR T-cell therapy in mice
This study is like watching a video of mice getting a new cancer treatment and then acting forgetful — and then checking their brains to see why. It shows a possible link between the treatment and brain changes, but it doesn't prove it happens the same way in people.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
This study found that a powerful cancer treatment called CAR T-cell therapy can accidentally trigger brain inflammation, which damages the brain's white matter and reduces new brain cell growth, leading to memory and attention problems.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 562 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — these changes are similar to brain fog experienced by human cancer survivors and could explain why some patients struggle with memory and focus after treatment.
- 2Mice with cancer treated with CAR T-cells had 20–35% fewer brain support cells (oligodendrocytes), 40–50% fewer new brain cells, and couldn't remember objects as well.
- 3These problems didn't happen in mice where the cancer cleared quickly or when the CAR T-cells didn't target the tumor.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cell
Year
2025
Authors
Anna C. Geraghty, Lehi Acosta-Alvarez, M. Rotiroti, Selena Dutton, Michael R. O’Dea, W. Kim, Vrunda Trivedi, Rebecca Mancusi, Kiarash Shamardani, K. Malacon, Pamelyn J. Woo, Naiara Martinez-Velez, T. Pham, Noemi Reche-Ley, Gabriel Otubu, Enrique H. Castenada, Kamsi Nwangwu, Haojun Xu, Sara B. Mulinyawe, D. Zamler, Lijun Ni, Kevin Cross, Justin Rustenhoven, Jonathan Kipnis, Shane A. Liddelow, Crystal L Mackall, R. Majzner, Michelle Monje
Related Content
Claims (6)
In mice with brain and non-brain cancers, CAR T-cell therapy is linked to ongoing brain inflammation, higher levels of specific inflammatory proteins in spinal fluid, activation of immune cells in white matter, loss of cells that make myelin, reduced growth of new brain cells in the hippocampus, and worse performance in attention and short-term memory tasks.
In mice receiving CAR T-cell therapy, higher levels of the protein CCL11 in the fluid surrounding the brain are linked to increased activation of immune cells in the brain, loss of cells that support nerve function, and reduced cognitive performance. Adding CCL11 alone reproduces these changes.
In mice treated with CAR T-cell therapy, temporarily reducing microglia activity with CSF1R inhibitors prevents oligodendrocyte loss and restores attention and short-term memory function, demonstrating that activated microglia directly contribute to cognitive deficits after neuroinflammation.
Blocking the CCR3 receptor in mice after CAR T-cell therapy reduces abnormal microglial activity, brings back oligodendrocyte cells, and improves attention and short-term memory.
In mice, cognitive and brain changes after CAR T-cell therapy occur because the immune system attacks cancer cells, not because the therapy binds to healthy tissues. Mice treated with CAR T-cells targeting non-brain tumors show no such changes.
In mice, inhibiting aged immune cells or the molecules they release results in improved cognitive function.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.